IceCure’s ProSense Cryoablation is Determined Safe & Effective Outpatient Procedure for Breast Cancer by Independent Study

(24/7 MARKET NEWS) – IceCure Medical Ltd. (NASDAQ: ICCM) stated, this morning, that new data, from a study that was conducted in Spain with women who declined standard of care surgery, was presented at the European Society of Breast Imaging (“EUSOBI”) Scientific Meeting in Valencia, Spain by Lucía Graña-López, MD, PhD, principal investigator of the independent, non-sponsored study.

IceCure Medical is trading at $$0.83, up $0.29 (+53.64%), on 534.78K premarket shares traded.

Its 52-week range is $0.52 to $4.73. It should fill the gap to about 90-cents, has a little resistance to $1.10 and its following key inflection point is $1.20, but keep in mind that this is a foreign based listing so swing or scalp trading is best.

 24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist